Nivolumab Treatment of Burkitt Lymphoma: A Case Report
Authors: B. Scott Colton, Nicholas Hornstein, John Timmerman, Sarah Larson, John Glaspy
Journal: Annals of Internal Medicine (2020)

LettersApril 2021Nivolumab Treatment of Burkitt Lymphoma: A Case ReportB. Scott Colton, MD, Nicholas Hornstein, MD, PhD, John Timmerman, MD, Sarah Larson, MD, and John Glaspy, MD, MPHB. Scott Colton, MDUniversity of California, Los Angeles, Los Angeles, California, Nicholas Hornstein, MD, PhDUniversity of California, Los Angeles, Los Angeles, California, John Timmerman, MDUniversity of California, Los Angeles, Los Angeles, California, Sarah Larson, MDUniversity of California, Los Angeles, Los Angeles, California, and John Glaspy, MD, MPHUniversity of California, Los Angeles, Los Angeles, CaliforniaAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/L20-1090 SectionsAboutFull TextPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail Background: Burkitt lymphoma is an uncommon form of lymphoma that affects approximately 1200 patients per year in the United States. It is aggressive and has a worse prognosis in older patients (1). During the past decade, high-dose chemotherapy regimens have been well tolerated and have dramatically improved event-free survival at 2 years, from 56% to 92% (2). However, successful treatment of refractory disease remains a formidable clinical challenge, especially when the disease is rapidly progressive.Objective: To describe successful treatment of refractory Burkitt lymphoma using nivolumab.Case Report: A 72-year-old man went to another hospital because of abdominal discomfort. He ...References1. Dunleavy K. Approach to the diagnosis and treatment of adult Burkitt's lymphoma. J Oncol Pract. 2018;14:665-71. [PMID: 30423267] doi: 10.1200/JOP.18.00148 CrossrefMedlineGoogle Scholar2. Magrath I, Adde M, Shad A, et al. Adults and children with small non-cleaved-cell lymphoma have a similar excellent outcome when treated with the same chemotherapy regimen. J Clin Oncol. 1996;14:925-34. [PMID: 8622041] CrossrefMedlineGoogle Scholar3. Ansell SM, Lesokhin AM, Borrello I, et al. PD-1 blockade with nivolumab in relapsed or refractory Hodgkin's lymphoma. N Engl J Med. 2015;372:311-9. [PMID: 25482239] doi: 10.1056/NEJMoa1411087 CrossrefMedlineGoogle Scholar4. Armand P, Rodig S, Melnichenko V, et al. Pembrolizumab in relapsed or refractory primary mediastinal large B-cell lymphoma. J Clin Oncol. 2019;37:3291-9. [PMID: 31609651] doi: 10.1200/JCO.19.01389 CrossrefMedlineGoogle Scholar5. Ansell SM, Minnema MC, Johnson P, et al. Nivolumab for relapsed/refractory diffuse large B-cell lymphoma in patients ineligible for or having failed autologous transplantation: a single-arm, phase II study. J Clin Oncol. 2019;37:481-9. [PMID: 30620669] doi: 10.1200/JCO.18.00766 CrossrefMedlineGoogle Scholar Author, Article, and Disclosure InformationAffiliations: University of California, Los Angeles, Los Angeles, CaliforniaAcknowledgment: The authors thank Sheeja Pullarkat with the UCLA Department of Pathology for providing pathologic results.Disclosures: Disclosures can be viewed at www.acponline.org/authors/icmje/ConflictOfInterestForms.do?msNum=L20-1090.Corresponding Author: B. Scott Colton, MD, University of California, Los Angeles, 100 UCLA Medical Plaza, Suites 550 and 555, Los Angeles, CA 90095; e-mail, [email protected]ucla.edu.This article was published at Annals.org on 27 October 2020. PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetails Metrics Cited byAntineoplastics April 2021Volume 174, Issue 4Page: 567-568KeywordsBurkitt lymphomaCellsChemotherapyDiffuse large B-cell lymphomaDisclosureHodgkin lymphomaLactate dehydrogenaseLymphomaMethotrexateProgressive diseases ePublished: 27 October 2020 Issue Published: April 2021 Copyright & PermissionsCopyright © 2020 by American College of Physicians. All Rights Reserved.PDF downloadLoading ...